ETFs positioned on Haleon plc

Name Weight AuM 1st Jan change Investor Rating
0.99% 11 M€ +0.83% -
0.94% 4 M€ +15.87%
0.21% 51 M€ +10.62%
0.17% 6 M€ -.--%
0.12% 10 M€ -3.35% -
0.11% 2 M€ +9.19% -
0.11% 2 M€ -.--% -
0.09% 37 M€ +7.81% -
0.09% 7 M€ +7.11% -
0.08% 794 M€ +10.01%
0.04% 205 M€ -.--%
0.04% 1,166 M€ +0.26% -
0.04% 607 M€ -0.19%
0.03% 0 M€ 0.00% -
0.03% 453 M€ +12.12% -
0.02% 39 M€ +10.63% -
0.02% 355 M€ +10.05% -
0.02% 45 M€ +8.47% -
0.01% 112 M€ +8.01% -
0.01% 273 M€ +17.41% -
0.01% 60 M€ +5.28% -
0.00% 7 M€ +0.11% -
0.00% 147 M€ +0.88% -
0.00% 25 M€ +0.49% -
Logo Haleon plc
Haleon plc specializes in the research, manufacture and marketing of drugs and consumer pharmaceutical products. Net sales break down by family of products as follows: - oral health products (27.7%; no. 1 worldwide): Sensodyne, Parodontax, Polident, Biotene, Aquafresh brands, etc.; - Pain relief medicines (23.5%; no. 1 worldwide): Panadol, Advil, Voltaren, Excedrin brands, etc.; - medicines for digestive health (18.9%; no. 1 worldwide): TUMS, Nicorette, ENO, Chap Stick, Fenistil, Nexium brands, etc.; - respiratory medicines (15.4%; no. 1 worldwide): Theraflu, Otrivin, Flonase, Contac brands, etc.; - vitamins, minerals and food supplements (14.5%; no. 1 worldwide): Centrum, Emergen-C, Caltrate brands, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa/Latin America (40.2%), North America (37.1%), and Asia/Pacific (22.7%).
Employees
25,408
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
3.874GBP
Average target price
3.865GBP
Spread / Average Target
-0.22%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW